SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

Share Price is delayed by 15 minutes
Get Live Data
73.50    0.50 (0.68%)
Bid:
72.00
Ask:
75.00
Spread: 3.00 (4.167%)
Market Cap: £306.68m
BSV Live PriceLast checked at - London Stock Exchange

Intraday Br.smaller Cos. Share Chart

3rd Quarter Results

19 Mar 2026 07:00

RNS Number : 2203X
British Smaller Companies VCT PLC
19 March 2026
 

British Smaller Companies VCT plc

Interim Management Statement for the quarter ended 31 December 2025

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 31 December 2025. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 31 December 2025 the Company's Total Return per share increased by 0.65 pence, a 0.8 per cent increase on the opening NAV per share. At 31 December 2025 the NAV per ordinary share totalled 78.70 pence, following payment of a 2.00 pence per share dividend in the quarter. 

Investment Activity

During the quarter, the Company invested £2.7 million into new investment TeamFeePay; and a further £4.1 million into existing portfolio companies Plandek, Xapien, Ohalo and Sipsynergy. Subsequent to the quarter end, the Company invested £3.0 million into existing portfolio company Summize. This takes the total amount invested so far this year to £18.5 million.

In October 2025, the Company realised its investment in Elucidat, receiving £5.5 million in initial proceeds, with additional deferred consideration of £0.7 million anticipated to be received over the next 18 months. To date, the Elucidat investment has generated a 1.3x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £6.2 million, and the return to 1.45x.

In December 2025, the Company realised its investment in SharpCloud, receiving £8.7 million in initial proceeds, with additional deferred consideration of £0.9 million anticipated to be received over the next two years. To date, the SharpCloud investment has generated a 2.0x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £9.6 million, and the return to 2.2x.

In December 2025, portfolio company Teraview successfully completed an oversubscribed listing on the Korean Stock Exchange. The Company subsequently realised 34 per cent of its holding prior to 31 December 2025, receiving proceeds of £1.2 million. The balance of the Company's holding was realised post-year end, in January 2026, generating a further £1.8 million of proceeds. Overall, the Teraview investment has generated an 8.1x return on the original cost of £0.4 million.

Post-year end, the Company realised its remaining holding in Vuealta, receiving proceeds of £0.7 million, in line with the valuation at the year end. Overall, the Vuealta investment has generated a 1.5x return on the original cost of £3.6 million.

The Company also realised its investment in Sipsynergy post-year end, with total expected proceeds of c. £0.9 million, in line with the valuation at the year end. This represents a 0.3x return on the original cost of £2.8 million.

 

Performance

The table below sets out movements in key metrics for the Company. 

 

 

30 September 2025

Net increase in Value

Shares issued

Dividends paid

Buyback of shares

Movement

In Period

31 December 2025

Net Assets (£m)

284.0

2.2

1.1

(7.1)

(1.7)

(5.5)

278.5

NAV per share (PPS)

80.05

0.65

-

(2.00)

-

(1.35)

78.70

Cumulative dividends paid (PPS)

186.15

-

-

2.00

-

2.00

188.15

Total Return (PPS)

266.20

0.65

-

-

-

0.65

266.85

Shares in issue

354,664,249

-

1,498,811

-

(2,231,911)

(733,100)

353,931,149

Cumulative dividends paid at 31 December 2025 were 188.15 pence per ordinary share (30 September 2025: 186.15 pence per ordinary share).

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 30 September 2025

284.0

80.05

Increase in portfolio value

2.5

0.75

Net operating costs

(0.3)

(0.10)

2.2

0.65

Issue/buy-back of shares

(0.6)

-

Total Return in the period

1.6

0.65

NAV before dividends

285.6

80.70

Dividends paid

(7.1)

(2.00)

NAV at 31 December 2025

 

278.5

 

78.70

 

Dividends and shares in issue

On 19 December 2025 the Company issued 1,498,811 shares under the Company's Dividend Re-investment Scheme (DRIS).

Under its standing buyback authority, on 19 December 2025 the Company purchased 2,231,911 shares at 74.65 pence per share at a cost of £1.7 million. These shares are held in treasury. 

The first allotment of the Company's 2025/26 fundraise took place just after the period end, with £15.6 million of proceeds allotted on 7 January 2026. 19,484,289 shares were allotted, taking the total number of ordinary shares to 373,415,438, with a further 39,260,029 shares held in treasury.

Net assets

Net assets at 31 December 2025 comprised the following:

£000

% of net assets

Unquoted investments at fair value

160,361

57.6

Cash and money market funds

113,825

40.9

Other net assets

4,350

1.5

Net assets

278,536

100.0

Investments

The investment portfolio at 31 December 2025 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

19,618

7.0%

Unbiased

16,584

13.0%

Xapien

14,255

18.1%

Vypr

11,315

22.2%

Summize

9,973

25.8%

AutomatePro

9,760

29.3%

DrDoctor

6,276

31.5%

Workbuzz

5,961

33.7%

Plandek

5,902

35.8%

Force24

5,841

37.9%

105,485

37.9%

Other investments

54,876

57.6%

Total investments

160,361

57.6%

 

Portfolio performance

In the quarter to 31 December 2025, the aggregate portfolio valuation increased by £2.5 million. Several portfolio companies are demonstrating strong underlying growth of revenues, which has driven positive revaluation uplifts across several assets. 

Fundraising

The Company announced a new share offer on 25 September 2025, alongside British Smaller Companies VCT2 plc, with the intention of raising up to £85 million, in aggregate, which included an over-allotment facility of £25 million, in aggregate. The offers closed to new Applications on 18 December 2025. Gross Applications of £85 million have been received, of which c.£53 million relate to the Company. The first allotment of £25 million (£15.6 million relating to the Company) took place on 7 January 2026; the second and final allotment will take place between 1 and 2 April 2026.

Outlook

The portfolio continues to develop, with several holdings delivering strong growth during the period. Our active portfolio management approach allows us to stay close to investee companies and support them as they scale. Adding new companies to the portfolio and providing follow-on capital to support their growth remains central to our strategy.

The start of 2026 has seen further macroeconomic volatility, with the conflict in the Middle East adding to a challenging environment. There has also been a more cautious market view of software businesses, which has the potential to weigh on the valuations of portfolio companies in the near term; nonetheless, the portfolio continues to be positioned to benefit from an increasingly AI-led world. This, alongside the Company's strong liquidity position leaves it well-placed to manage downside risks, as well as deploy funds from its recent capital raise into promising new opportunities across the UK. 

We are grateful to shareholders for their continued support.

18 March 2026

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

For further information please contact:

Marcus Karia YFM Equity Partners Tel: 0113 244 1000

Alex Collins Panmure Liberum Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTEAEDPFEDKEAA
Date   Source Headline
1st Apr 20104:39 pmRNSIssue of Equity
30th Mar 20101:06 pmRNSOffer Update - Close of Offer
1st Mar 20108:42 amRNSPotential Transaction
29th Jan 20107:00 amRNSInterim Management Statement to 31 December 2009
8th Jan 20109:14 amRNSIssue of Equity
23rd Dec 20094:22 pmRNSTransaction in Own Shares
20th Nov 20097:00 amRNSHalf Yearly Report to 30 September 2009
14th Aug 20097:00 amRNSInterim Management Statement
14th Aug 20097:00 amRNSIssue of Equity and Total Voting Rights
7th Aug 20091:07 pmRNSAGM Statement
13th Jul 200910:29 amRNSDoc re. Annual Report for year ended 31 March 2009
8th Jul 20095:59 pmRNSDoc re. Circular to Shareholders
3rd Jul 20093:25 pmRNSTransaction in Own Shares
26th Jun 20093:42 pmRNSAnnual Financial Report - Replacement
26th Jun 20092:23 pmRNSAnnual Financial Report Announcment
11th Feb 200911:33 amRNSIssue of Equity and Total Voting Rights
20th Jan 20099:50 amRNSInterim Management Statement
15th Jan 20094:09 pmRNSIssue of Equity and New Articles - Amendment
15th Jan 20091:46 pmRNSIssue of Equity and New Articles
16th Dec 20088:47 amRNSInterim Report and Circular to Shareholders
20th Nov 200811:00 amRNSHalf Year Financial Statements
1st Oct 20089:16 amRNSTransaction in Own Shares
8th Aug 20089:33 amRNSInterim Management Statement
7th Aug 20084:39 pmRNSAGM Statement
15th Jul 20084:08 pmRNSAnnual Report and Accounts
11th Jul 200811:31 amRNSPurchase of Own Shares and To
3rd Jul 20088:47 amRNSUnaudited Preliminary Results
1st Jul 20089:59 amRNSDirector Change
1st May 20083:48 pmRNSIssue of Equity
7th Apr 20083:53 pmRNSAllotment of shares and TVR
3rd Apr 20084:31 pmRNSCirc re. Fund Manager
1st Apr 200812:53 pmRNSPurchase of shares and TVR
29th Feb 200812:57 pmRNSDirectorate Change
20th Feb 20083:21 pmRNSPurchase of own shares & TVR
14th Feb 20083:25 pmRNSPurchase of shares and TVR
6th Feb 20084:32 pmRNSEGM Statement
24th Jan 20084:11 pmRNSInterim Management Statement
4th Jan 20084:04 pmRNSOffer for Subscription
30th Nov 20071:21 pmRNSPurchase of shares and TVR
17th Oct 200710:25 amRNSInterim Results
28th Sep 20074:56 pmRNSShare Buyback & Voting Rights
6th Sep 20079:37 amRNSAnnouncement re Cozart plc
5th Sep 20075:02 pmRNSSale of holding in Cozart plc
9th Aug 20079:53 amRNSInterim Management Statement
8th Aug 200712:47 pmRNSPurchase of Own Shares
1st Aug 20071:55 pmRNSIssue of Equity
29th Jun 20074:54 pmRNSTotal Voting Rights
29th Jun 20074:50 pmRNSTransaction in Own Shares
22nd Jun 200712:28 pmRNSTotal Voting Rights
12th Jun 20072:42 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.